Navigation Links
New Critical Path Report Highlights Research Needed to Foster Generic Drug Development

The U.S. Food and Drug Administration (FDA) today issued the "Critical Path Opportunities for Generic Drugs" report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

The report is part of FDA's Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product. Solving these challenges will require the expertise and input of many groups, including scientists from universities, patient groups, government, industry, associations and other private organizations.

"This report pinpoints the barriers that are limiting the availability of additional generic drug options," said Gary Buehler, R.Ph., director, FDA's Office of Generic Drugs. "We hope these findings will encourage research collaboration, lower these barriers and accelerate access to safe and effective generic drugs."

Before they can be approved, generic drugs must have the same active ingredient, dosage form, strength, and conditions of use as the brand name drug. The drugs must also be absorbed at the same rate and in the same amount, a concept known as bioequivalence.

While straightforward tests of blood plasma levels are sufficient to demonstrate bioequivalence for most generic drug candidates, these common tests generally are not appropriate for certain drugs, including asthma inhalers, nasal sprays, and topical skin applications such as anti-fungal creams. As a result, few generic versions are available in these product categories, resulting in less competition and higher prices.

For example, generic drug products that contain the ozone-depleting substance chlorofluorocarbon will be withdrawn from the market after 2008. The new report will help ensure FDA has an adequate scientific basis to review inhaler applications tha t use an alternative, hydrofluoroalkane.

The report also calls for research on new bioequivalence methods tailor-made for each challenging drug class. These include lung function tests and molecular level imaging for inhalation drugs; particle size distribution tests for nasal sprays; and methods for direct measurement of drug delivered to the skin.

In addition, the report highlights possible research projects that might lead to new modeling and simulation tools for drug absorption, drug release and other drug development issues and to alternative methods for seeking waivers from clinical bioequivalence studies.

Last year FDA issued the Critical Path Opportunities Report listing 76 specific scientific projects that, if undertaken, would help modernize the Critical Path sciences. This companion document focuses more narrowly on the scientific challenges unique to the development of generic drugs.


'"/>




Related medicine news :

1. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
2. Sleep Not Critical For Early Brain Development Of Baby Dolphins
3. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
4. Dietary supplementation of Folic Acid Requires Critical Evaluation
5. Past President Narayanans Condition Still Critical
6. Critical Decisions Have To Be Taken By Mothers Of Premature Babies
7. Heart Transplant Twin Recovering, But Brother Critical
8. Australia In Search Of A Better Way to Handle Critically Ill Patients and Balance Elective Surgery
9. Yeast Genome Unravels Genes Critical For Maintaining DNA Integrity
10. Drug Trial Goes Foul, Six Volunteers Critically Ill
11. Sensory Input Necessary During "Critical Periods" Of Brain Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... On Sunday, September 24, hundreds will gather ... Florence Joyner, still considered the fastest woman of all time. Flo Jo passed ... Joyner, will sing the National Anthem. Mary was a contestant on the 2012 ...
(Date:9/22/2017)... ... 22, 2017 , ... After a long health ordeal that ... lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief and debt ... debt. The senior is one of the satisfied clients who expressed their appreciation ...
(Date:9/22/2017)... ... ... Pullano Law Offices, a Chicago personal injury law firm, is pleased to ... as President of the North Suburban Bar Association for 2017-2018. Mr. Pullano was installed ... NSBA at the North Shore Country Club in Glenview, IL, on September 13, 2017. ...
(Date:9/22/2017)... ... 22, 2017 , ... "Success Files," a short- and long-form ... is a disease estimated to affect the lives of more than 5 million ... Association, a leading voice in the fight for cure and research into the ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... more products at customers’ doorstep. According to Smart Mart, customers can now order ... to offer wearable, and customers can find clothing at discounted prices. Apart from ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), the ... and tissue hypothermic storage and cryopreservation freeze ... and CEO, will be presenting at two investment conferences in ... th Annual Global Investment Conference on Tuesday, September 12th, ... conference is being held at the New York Palace Hotel ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology: